Interstitial Pneumonia with HLA-B54 Antigen that Responded Well to Erythromycin

Intern Med. 2022 Dec 1;61(23):3559-3562. doi: 10.2169/internalmedicine.9304-21. Epub 2022 Apr 23.

Abstract

A 65-year-old Japanese man with interstitial pneumonia demonstrated honeycomb lung with thickened walls on chest high-resolution computed tomography (HRCT) and predominance of neutrophils in the cell fraction of the bronchoalveolar lavage fluid. Although there were no centrilobular nodular or branching shadows on chest HRCT suggestive of diffuse panbronchiolitis, he exhibited sinusitis and had the human leukocyte antigen (HLA)-B54 antigen. With long-term macrolide therapy, the cough and sputum production markedly improved, wall thickening of the honeycomb lung on chest HRCT decreased, and the forced vital capacity increased. Confirming the presence of HLA-B54 antigen may help determine the indication for long-term macrolide therapy in interstitial pneumonia patients.

Keywords: HLA-B54 antigen; diffuse panbronchiolitis; erythromycin; interstitial pneumonia; macrolide.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Erythromycin* / pharmacology
  • Erythromycin* / therapeutic use
  • HLA-B Antigens
  • Humans
  • Lung Diseases, Interstitial* / diagnostic imaging
  • Lung Diseases, Interstitial* / drug therapy
  • Macrolides
  • Male

Substances

  • Erythromycin
  • HLA-B54 antigen
  • HLA-B Antigens
  • Macrolides
  • Anti-Bacterial Agents